Company ProfilePremium

COSON Co., Ltd.

Company Profile Analysis

Ticker: 069110.KQ주식회사 코스온

ESOMAR 23 Corporate BadgeISO Certifications Badge
COSON Co., Ltd. - Company showcase

Year Founded & Workforce

1992

39 Employees

COSON Co., Ltd. logo

COSON Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

COSON Co., Ltd. Overview

Yuhan Cosmetics, formerly COSON, is a small South Korean cosmetics OEM/ODM manufacturer that is being rebuilt by its controlling shareholder, Yuhan Corporation, one of Korea's largest pharmaceutical companies. Between 2014 and 2019, COSON grew from a reverse-listed DVR maker into a top-tier colour-cosmetics contract manufacturer, peaking at roughly KRW 109 bn of revenue in FY2019. Its growth came from co-developing YG Entertainment's Moonshot brand (including the "GD Cushion"), private-label supply to MINISO through a Guangzhou subsidiary, and China-facing distribution. The 2017 THAAD retaliation, failed brand ventures, COVID-19, three consecutive audit disclaimers (FY2020–FY2022), court rehabilitation (2022–2023) and KOSDAQ delisting (October 2023) collapsed the business. FY2025 revenue was about KRW 1.9 bn against an operating loss of KRW 5.8 bn. Equity was negative KRW 27.8 bn at end-Q1 2026. The investment case now rests on Yuhan's continued funding and on whether the "Trusted Science, Beautiful Solutions" pharma-linked ODM repositioning can win new customers.


What the company does

Yuhan Cosmetics develops and manufactures cosmetic products under contract for brand owners (OEM: manufacturing to the customer's formula; ODM: the manufacturer develops and proposes the formula). Historically the product scope covered both skin care and colour cosmetics. Simply Wall St's description lists skin-care formats (solubilised products, masks, cleansing, emulsions, sun care) and make-up formats (emulsion-based, lip and powder products). Trade databases also record BB and CC creams.

Company's own description (paraphrased)

At the October 2025 renaming, the company set out a vision of "Trusted Science, Beautiful Solutions." It says it will combine Yuhan Corporation's accumulated scientific research know-how with cosmetics development, offering an end-to-end service from product planning through R&D, production and quality control. It named three core values: Innovation First, Trusted Partnership and Sustainable Growth. It also named excellence, scientific approach and partnership as guiding principles, and committed to continued R&D investment (Herald Economy; Hankyung, Oct 2025).

Independent characterisation

On the evidence, the company today is a sub-scale, loss-making contract manufacturer in turnaround. Revenue in FY2025 (KRW 1.9 bn) was about 1.7% of its FY2019 peak (KRW 109.3 bn). Quarterly revenue in 2026 has run at about KRW 0.4 bn, while quarterly operating losses have been KRW 0.9–1.4 bn (Dailypharm, Jul 2026). Its balance sheet is fully impaired (equity of negative KRW 27.8 bn at end-Q1 2026). The business continues because Yuhan Corporation keeps injecting equity: KRW 105 bn... correction, KRW 10.5 bn across three issues in 2025, and KRW 5.0 bn approved in July 2026.

The model has two strands:

  1. B2B contract manufacturing (core). Revenue is per-unit manufacturing fees, with margins driven by plant utilisation.

  2. Own-brand B2C (nascent). The subsidiary Yucostory sells the "The Yu" (더이유) brand on Naver Smart Store; Yuhan Cosmetics manufactures it (Mar 2026).

Revenue model mix

Revenue streamShare of revenueStatus
Product manufacturing (OEM/ODM)Not publicly disclosed; historically the large majorityCore
Own brands (Moonshot co-venture historically; The Yu from 2026)—Nascent
Services / subscription / licensingNone disclosed—

Value-chain position and customers

The company sits in the mid-stream of the beauty value chain. It buys raw materials and packaging, formulates and fills, and supplies finished goods to brand owners, who handle marketing and retail. Named historical customers and partners include:

  • YG Entertainment's Moonshot brand (development and production);

  • MINISO private-label products and the Chinese colour brand "Wushenji" (우센지) via the Guangzhou subsidiary (2017);

  • Guangzhou Huanya Cosmetics (distribution partner, 2014);

  • apM Group (Dongdaemun) private-label and collaboration products (2016);

  • a US consignee, Astral Health and Beauty, which received shipments through June 2023 (Panjiva).

End-markets

Mass and masstige skin care and colour cosmetics, sold domestically through retail, duty-free and online channels, and exported through brand customers, historically with heavy exposure to China.

Strategy

Stated strategy (themes paraphrased)

  1. Pharma-science-led ODM. Use Yuhan's research know-how and quality systems to differentiate in formulation, safety and QC (Oct 2025 renaming).

  2. Full-service partner. Cover planning, R&D, production and QC, and focus on customers' brand goals.

  3. Diversify into own brands. Launch "The Yu" through Yucostory (2026), with KRW 1.0 bn of the July 2026 raise earmarked for new brand development.

  4. Capacity refresh. KRW 1.2 bn for an additional cell line and KRW 1.8 bn for filling, analysis and testing equipment (Jul 2026).

  5. Comprehensive ODM/OEM ambition. At the April 2024 "second founding," management presented a medium- to long-term plan to become a comprehensive ODM/OEM company. Detailed targets were not disclosed.

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

DateInitiativeDetail
Jan 2025Equity injectionKRW 3.0 bn rights issue to Yuhan
Sep 2025Equity injectionKRW 2.5 bn rights issue to Yuhan
Oct 2025Equity injection and rebrandKRW 5.0 bn rights issue; renamed Yuhan Cosmetics; new vision and values
Q4 2025New subsidiaryYucostory (100%, KRW 5 m capital) for B2C sales
Early 2026Own-brand launch"The Yu" vita-exosome mist, cream and ampoule on Naver Store
Mar–Apr 2026Capital-structure event (third party)Sungwoo Electronics' attempted KRW 15 bn sale of its BW, cancelled
Jul 2026RCPS fundingKRW 5.0 bn RCPS to Yuhan (4,545,454 shares; redemption window 28 Jul 2028 – 28 Jul 2031 at KRW 1,100 per share; conversion from 28 Jul 2027)

ESG commitments and cost programmes

No quantified ESG commitments or cost-reduction targets are disclosed. "Sustainable Growth" is named as a core value without metrics.

Medium-term financial targets

None publicly disclosed. A management representative said in January 2024 that the goal of rehabilitation was to reduce debt and return to past revenue levels (Hitnews, paraphrased). No figures were attached.

Products & Services

The company has not published a current product catalogue in sources reviewed. The list below compiles products and formats named in filings, press and trade data. Pricing is not disclosed for any contract-manufactured item.

Contract manufacturing formats (OEM/ODM)

CategoryFormatsTarget customerNotes
Skin careSolubilised products (toners, essences), masks, cleansing, emulsions (lotions, creams), sun careBrand ownersSimply Wall St description
Base make-upBB creams, CC creams, cushion foundationsBrand ownersEMIS; Moonshot products
Colour cosmeticsLip products, powders, emulsion-based make-upBrand ownersOsan plant made colour possible from March 2014
Private labelRetailer own-brand cosmeticsMINISO (China), apM Group (Korea)2016–2017

Named flagship and brand-linked products

Product / lineBrand ownerYearDescription
Micro Fit Cushion ("GD Cushion")Moonshot (YG)c.2015Cushion foundation named after G-Dragon; Time Out describes it as long-wearing and light-textured
Moonshot launch range (208 SKUs)Moonshot (YG)Oct 201421 skin care, 23 base make-up and 162 colour items, aimed at women aged 20–39
Powder Duo (e.g., Minty Wind, Aries Scent)Moonshot2,015Eye colour duo, S/S 2015 collection
Neutral Skin Illuminator SPF50 PA+++Moonshot2,015Tone-up base used in duty-free promotions
Colour Moonwalk Cream PaintMoonshot2,015Cream colour product
Perfect Cleansing WaterMoonshot2,015Cleansing water
Lipstick line inspired by BLACKPINK (16 shades)Moonshot2,018Matte and semi-matte shades
MINISO private-label cosmeticsMINISO2,017Supplied from Guangzhou subsidiary
Wushenji colour cosmeticsWushenji (China)2,017Supplied from Guangzhou subsidiary

Note: COSON's manufacturing role is documented for the Moonshot brand overall. Plant-level attribution of each individual Moonshot SKU is not disclosed.

Own brand (2026)

ProductBrandChannelManufacturer
Vita Exosome Capsule MistThe Yu (더이유)Naver Store via YucostoryYuhan Cosmetics
Vita Exosome Moisture CreamThe YuNaver Store via YucostoryYuhan Cosmetics
Vita Exosome AmpouleThe YuNaver Store via YucostoryYuhan Cosmetics

Pricing, sales volumes and launch dates beyond "early 2026" are not publicly disclosed.

Financial Narrative

Disclosure caveats

  • FY2020, FY2021 and FY2022 financial statements received auditor disclaimers of opinion. Figures for those years are unaudited in substance and should be used with caution.

  • FY2023 received an unqualified ("appropriate") opinion (Jangup Shinmun, Apr 2024).

  • After delisting, only headline revenue and operating income (via Dailypharm and Cosinkorea, citing FSS filings) and an end-Q1 2026 balance-sheet summary are publicly reported. Gross profit, EBITDA, net income, EPS and cash flows are not available for most years.

Income statement (FY2021–FY2025)

Sources: Dailypharm (23 Jul 2026; 3 Sep 2025; 7 Apr 2023), citing FSS filings. Growth and margins computed. Cosinkorea (Apr 2026) gives the FY2024→FY2025 decline as 53.2% using unrounded figures. No dividends are recorded in any source reviewed; zero is shown on that basis.

Revenue CAGR FY2021–FY2025: about -50.5% per year (KRW 31.6 bn → 1.9 bn).

Aggregator data point (TTM to 30 Jun 2023, Simply Wall St): revenue KRW 10.5 bn; cost of revenue KRW 13.8 bn; gross profit -KRW 3.3 bn; other expenses KRW 19.3 bn; earnings -KRW 22.7 bn. This shows that even gross margin was negative during the rehabilitation period.

Long-run revenue and profit history (FY2013–FY2025)

Sources: FY2013 Cosinkorea (2018); FY2014–FY2017 Edaily and Etoday (Mar 2018); FY2015–FY2016 operating and net income Cosmorning (2017, consolidated); FY2019–FY2025 Dailypharm (2025–2026). FY2018 revenue exceeded KRW 100 bn (Dailypharm states three consecutive years above KRW 100 bn in FY2017–FY2019), but the exact figure was not found.

Source conflicts noted:

  • Etnews (Dec 2015) cites FY2015 standalone revenue of KRW 15.5 bn and operating income of KRW 1.5 bn, against KRW 61.9 bn consolidated. The two bases are not reconcilable from public data and may reflect a partial period.

  • FY2017 revenue appears as KRW 100.4 bn (Edaily) and KRW 100.5 bn (Cosinkorea).

  • Cosmorning (Apr 2018) lists COSON among companies whose FY2017 profit fell 76.5%, without specifying the exact metric in the excerpt reviewed. FY2017 operating income is therefore left blank.

Balance sheet

Latest disclosed position (end-Q1 FY2026, Dailypharm): total assets KRW 19.4 bn; total liabilities KRW 47.2 bn; total equity -KRW 27.8 bn (complete capital impairment). Liabilities were more than twice assets.

Historical capital structure (end-Q1 FY2019, DART via Findata): share capital KRW 11.1 bn (18,697,161 common and 3,511,632 preferred shares). The CEO had personally guaranteed bank borrowings from Woori, Kookmin, Hana, Shinhan and KDB totalling KRW 23.1 bn, plus about KRW 1.0 bn of performance guarantees via Seoul Guarantee Insurance (KRW 24.1 bn combined in that table).

Cash flow

Equity raised: Dailypharm. In FY2024 Sungwoo Electronics also subscribed KRW 10 bn of bonds with warrants (debt with equity option). No buybacks or dividends are recorded; zeros are shown on that basis.

Ratios

With negative equity (end-Q1 2026) and negative operating income in every year since FY2020, ROE, debt/equity, net debt/EBITDA and interest coverage are not meaningful even where inputs exist. The only computable leverage indicator is liabilities/assets of about 2.4x at end-Q1 2026 (47.2 / 19.4).

Commentary on trends, inflections and drivers

Growth phase (FY2013–FY2019). Revenue grew about tenfold, from KRW 10.6 bn (FY2013) to KRW 109.3 bn (FY2019). Three drivers stand out. First, the March 2014 start-up of the Osan plant added colour cosmetics capacity. Second, the YG/Moonshot partnership gave COSON visibility and volume. Third, the Guangzhou subsidiary won MINISO private-label business, which offset THAAD-related weakness in 2017. In this phase COSON was consistently profitable at the operating line (it posted no operating loss between FY2015 and FY2019, per Chosun Biz's statement that FY2020 was its first loss since 2014). FY2015–FY2016 operating margins were about 10–11%.

First inflection (FY2017). Sell-side forecasts (Hyundai Securities, Dec 2016) expected FY2017 operating income near KRW 19.9 bn on KRW 103.3 bn of revenue. Revenue arrived broadly on target, but profitability fell sharply (Cosmorning's 76.5% decline reference). This suggests brand-side costs and mix deterioration, with China exposure the critical swing factor after THAAD.

Collapse (FY2020–FY2022). Revenue fell 16% in FY2020 and then 66% in each of FY2021 and FY2022. Operating losses of KRW 14.7 bn and 15.0 bn in FY2020–FY2021 exceeded the best annual operating profit of the growth phase. Chosun Biz attributes the turn to anti-Korea sentiment in China and the rise of Chinese domestic brands. Press accounts also point to weak brand businesses. The audit disclaimers then cut off normal financing, and the company entered court rehabilitation in April 2022.

Post-rehabilitation (FY2023–H1 FY2026). Operating losses have narrowed in absolute terms (KRW 7.0 bn → 5.8 bn), but revenue has kept falling faster than costs. By Q2 2026 the quarterly operating loss was more than three times quarterly revenue. The company is not yet showing revenue stabilisation; cost reduction alone has not been enough to approach breakeven.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Segment Margins & Growth (%)

SegmentFY2023FY2024FY2025

Cosmetics manufacturing and sales revenue (KRW Bn)

7.54.01.9

Cosmetics operating income (KRW Bn)

-7.0-5.9-5.8

Operating margin (%)

-93.3-147.5-305.3

Share of total revenue (%)

100100100

Group Entities

EntityOwnershipFunctionStatus

Yuhan Cosmetics Co., Ltd. (parent)

Yuhan Corp. largest holder

ODM/OEM manufacturing

Operating

Yucostory (유코스토리)

100%

Online sale of the "The Yu" brand

Founded Q4 2025

Guangzhou COSON (China)

—

Historical China plant (MINISO PB)

Current status not disclosed

Hong Kong JV with Guangzhou Huanya (and YG participation)

—

China brand and distribution vehicle (2014)

Current status not disclosed

“—” = not publicly disclosed.

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

31.610.67.54.01.9

Revenue growth YoY (%)

-65.6-66.5-29.2-46.7-52.5

Operating income (KRW Bn)

-15.0-9.6-7.0-5.9-5.8

Dividends per share (KRW)

00000

Operating margin (%)

-47.5-90.6-93.3-147.5-305.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement

MetricFY2013FY2014FY2015FY2016FY2017FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

10.626.461.983.1100.4109.391.931.610.67.54.01.9

Operating income (KRW Bn)

——6.98.1——-14.7-15.0-9.6-7.0-5.9-5.8

Net income (KRW Bn)

——4.56.8————————

Revenue History

PeriodRevenue (KRW Bn)Operating income (KRW Bn)Net income (KRW Bn)Source

H1 FY2017

49.4 (+18.8% YoY)

4.2 (+10.4%)

3.0 (+13.2%)

Cosmorning, Aug 2017

Q1 FY2026

0.4-0.9—

Dailypharm, Jul 2026

Q2 FY2026

0.4-1.4—

Dailypharm, Jul 2026

“—” = not publicly disclosed.

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Dividends paid (KRW Bn)

00000

Share buybacks (KRW Bn)

00000

Equity raised from Yuhan Corp. (KRW Bn)

0005.010.5

Revenue by Region

RegionFY2023FY2024FY2025

Total (KRW Bn)

7.54.01.9

Capital Markets

ItemValueSource

Trading halt

From March 2021 (audit disclaimer) to 10 October 2023

Dealsite

Liquidation trading

11–19 October 2023

Cosinkorea

First-day liquidation move

-87.76%

Cosinkorea

Week of liquidation start

-92.05%

Cosinkorea

Last aggregator market capitalisation

KRW 4.4 bn

Simply Wall St (stale)

Analyst Ratings & Targets

DateBrokerRatingKey call

20 Jun 2014

Woori Investment & Securities

Target price KRW 7,750

Described as the cosmetics name with the highest China growth potential; 3-year revenue and operating-income CAGR forecasts of 38.3% and 57.5%

7 Apr 2016

Daishin Securities

Buy

Q1 FY2016 standalone revenue forecast KRW 19.1 bn (+54% YoY)

12 Apr 2016

Hana Financial Investment

Not rated

Expected revenue and operating income growth above 50% YoY

31 Oct 2016

Hanyang Securities

Not rated

China acceleration

1 Dec 2016

Hyundai Securities

Buy

FY2017E revenue KRW 103.3 bn, operating income KRW 19.9 bn

25 Aug 2017

Golden Bridge Investment & Securities

Coverage dropped

—

22 Nov 2017

Taurus Investment & Securities

Buy

FY2018 earnings upturn expected

Valuation Multiples

MultipleYuhan CosmeticsPeers

P/E

Not applicable (unlisted; loss-making)

Not compiled

EV/EBITDA

Not applicable

Not compiled

EV/Sales

Not applicable

Not compiled

P/B

Not applicable (negative equity)

Not compiled

Capital Markets — Dividend history

ItemStatus

Dividend history

No dividends recorded in sources reviewed

Moody's / S&P / Fitch ratings

Not rated

Debt maturity profile

Not disclosed. Known instruments: Sungwoo BW (KRW 10 bn, 2024; maturity not disclosed); Yuhan RCPS redeemable 28 Jul 2028 – 28 Jul 2031

Analyst Conclusions

Management guidance and consensus

There is no published financial guidance and no consensus forecast. Management's stated aims are qualitative: become a trusted, science-based ODM partner, build new brands, and return toward historical revenue levels.

Bull-case arguments

  1. Strong, patient parent. Yuhan has shown willingness to fund repeatedly: five injections over 2024–2026 plus the July 2026 RCPS. Its record FY2025 earnings (operating income KRW 104.4 bn) make a few billion won a year affordable.

  2. Market tailwind. Korean cosmetics exports hit records in 2025 (US$11.4 bn) and grew 27% in H1 2026. The 81-company ODM sector grew revenue 11.8%. Even a small share of indie-brand overflow would multiply the current KRW 1.9 bn revenue base.

  3. Operating leverage. Fixed costs are already sunk in an existing CGMP plant. Each incremental contract drops through at high marginal contribution, so modest wins could narrow losses quickly.

Bear-case arguments

  1. Revenue still falling. Revenue declined in each of the last six years and fell again in 2026 (KRW 0.4 bn per quarter), despite rebranding and new funding. Nothing in the data yet shows that customers are returning.

  2. Balance sheet. Equity of -KRW 27.8 bn and liabilities of KRW 47.2 bn mean the business would be insolvent without parent support. Hybrid instruments (BW, RCPS) add future claims.

  3. Structural competition. Cosmax and Kolmar earn 8–9% margins at about KRW 2.4–2.7 trillion revenue and offer global plants, deep R&D and proven reliability. Indie brands prioritise speed and minimum-order flexibility, where incumbents and many nimble small ODMs already compete.

Catalysts and monitorables (next 12 months)

ItemWhy it matters
Q3 and Q4 FY2026 revenueAny quarter above KRW 1 bn would signal real customer wins
FY2026 audit opinionMust remain unqualified
Deployment of July 2026 capex (cell line, filling, testing)Indicates capacity readiness
Sell-through of "The Yu"Test of B2C viability
Resolution of the Sungwoo BW / warrant overhangOwnership clarity
Any captive contracts from Yuhan group businessesEasiest route to base-load volume
Further Yuhan funding decisionsSignal of continued parent commitment
Conversion of RCPS (from July 2027) or redemption (from July 2028)Capital-structure clarity

Concluding analyst verdict

COSON's arc, from a reverse-listed DVR shell to Korea's fourth-ranked colour-cosmetics ODM and then to a delisted, capital-impaired micro-manufacturer, is a cautionary example of K-beauty's China-dependent boom. Between FY2013 and FY2019 the company showed genuine formulation skill and commercial agility. Revenue rose tenfold to about KRW 109 bn, supported by the Moonshot partnership and MINISO private-label supply. That growth rested on concentrated customers and China exposure. When THAAD retaliation, failed brand bets and COVID-19 arrived together, weak financial controls (three consecutive audit disclaimers) turned an operating downturn into a solvency and listing crisis.

The successor entity, Yuhan Cosmetics, is best analysed as a strategic option held by Yuhan Corporation rather than as a standalone investment. Its FY2025 revenue of KRW 1.9 bn and KRW 5.8 bn operating loss, along with negative equity of KRW 27.8 bn at end-Q1 2026, mean value depends almost entirely on the parent's continued willingness to fund and on the plant's ability to win new contracts. The external backdrop is the best it has been in a decade: record Korean exports, a growing ODM sector and indie brands that need outsourced capacity. Yet the company's revenue has kept falling through 2026 despite rebranding.

On balance, the evidence supports a high-risk, binary outlook. A credible turnaround requires visible quarterly revenue growth in H2 2026 and FY2027, a sustained clean audit, and ideally captive or anchor volume from Yuhan group businesses. Absent these signs within the next 12–18 months, the more probable outcomes are further dilutive recapitalisation by Yuhan, an eventual merger into a Yuhan affiliate, or a sale of the Osan asset. For external stakeholders such as customers, suppliers and creditors, exposure should be underwritten against Yuhan's support, not against Yuhan Cosmetics' own balance sheet.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackground

Lee Jong-ho (이종호)

Co-CEO

By Oct 2025; start date not disclosed

—

Cho Il-hyun (조일현)

Co-CEO

By Oct 2025; start date not disclosed

—

Kim Jae-yong (김재용)

Non-executive director

By 2024

Head of Planning & Finance, Yuhan Corporation

Kim Dong-geun (김동근)

Statutory auditor

By 2024

Commercialisation Strategy team leader, Yuhan Corporation

Lee Dong-geon (이동건)

CEO; also court-appointed custodian during rehabilitation

Nov 2012 – at least May 2023 (term to Nov 2024)

Born Jan 1968; B.S. and M.S. Chemical Engineering, Yonsei University; senior researcher at Pacific (Amorepacific) R&D; former CEO of Navion and Mizon. Held 2,504,907 shares (Q1 FY2023)

Byun Jae-han (변재한)

Head of Finance & Accounting (non-registered)

About 13 years to 2023

Former accounting team head at Daea Lead Wire and at 3H

Han Sang-ho (한상호)

CEO of 3H

Nov 2007 – Nov 2012

—

Kim Dong-yeon (김동연)

CEO of Picaso Info & Comm

to Nov 2007

—

Kim Hee-sun (김희선)

Marketing executive (Managing Director)

c.2015

Ran the Trend Lab initiative

Choi Young-wook (최영욱)

Inside director (cross-appointed)

2,020

CEO of Audin Futures

“—” = not publicly disclosed.

Major Shareholders

HolderStakeDateSource

Yuhan Corporation

25.43% of common; 21.69% of preferred

End-Q1 2026

Dailypharm, Jul 2026

Yuhan Corporation

32.5% (common basis)

End-2025

Press via Nate, Mar 2026

Yuhan Corporation

32.5% (11.73 m shares)

Apr 2024

Jangup Shinmun

Sungwoo Electronics (KOSDAQ: 081580)

Warrants over 9,090,909 shares (25.18% of total, as reported)

Jul 2024

Dailypharm, Jul 2024

Cruise Holdings (크루즈홀딩스)

Allotted one-third of the first Jan 2024 issue (2 m shares implied)

Jan 2024

Hitnews

Baytree (베이트리)

15.3% (20,980,102 shares), briefly largest

Sep 2023

Dailypharm, Nov 2023

Lee Dong-geon (former CEO)

11.28%

Q1 2019

Findata (DART)

Governance Overview

MetricFY2015FY2018FY2019FY2023FY2024

Yuhan stake (%)

3.8812.312.1811.432.5

Competitive Landscape

Key Competitors

CompetitorListingFY2025 revenue (KRW Bn)FY2025 operating income (KRW Bn)Positioning vs. Yuhan CosmeticsSource

Kolmar Korea

KOSPI

2722.4 (consolidated)

239.6

Largest by revenue; skin care, sun care, pharma via HK inno.N

Herald Economy, Feb 2026

Cosmax

KOSPI

2,398.8195.8

World's largest pure-play cosmetics ODM; strong colour; China, US, SE Asia plants

Sidae, Feb 2026

Cosmecca Korea

KOSDAQ

—83.5

Third of Korea's "big three" ODMs; US subsidiary Englewood Lab

Cosinkorea, Apr 2026

Englewood Lab

KOSDAQ

—37.4

US-based ODM controlled by Cosmecca

Cosinkorea, Apr 2026

Korea Cosmetics Manufacturing

KOSPI

—32.9

Domestic ODM

Cosinkorea, Apr 2026

Intercos Korea

Unlisted (Intercos group)

——

Colour-cosmetics ODM, also in Osan (Gajang industrial complex)

Cosmorning

Cosvision

Unlisted

——

Mid-tier ODM (FY2017 revenue KRW 185.8 bn)

Cosinkorea, 2018

C&F (씨엔에프)

Unlisted

——

Mid-tier ODM (FY2017 revenue KRW 147.2 bn)

Cosinkorea, 2018

CTK Cosmetics

KOSDAQ

——

Colour-cosmetics ODM

CNC News

Yuhan Cosmetics (subject)

Unlisted

1.9-5.8

Micro-scale; turnaround

Dailypharm

“—” = not publicly disclosed.

Peer Comparison FY2025

MetricYuhan CosmeticsKolmar KoreaCosmaxCosmecca Korea

Revenue (KRW Bn)

1.92,722.42,398.8—

Revenue growth YoY (%)

-52.5—10.7—

Operating income (KRW Bn)

-5.8239.6195.883.5

Operating margin (%)

-305.38.88.2

not computable

“—” = not publicly disclosed.

Recent Developments

The table records every development found in the window, followed by earlier context that remains relevant.

Leadership changes, guidance revisions, litigation, layoffs and hiring:* none publicly reported in the 18-month window beyond the co-CEO arrangement disclosed at the renaming.

Company Snapshot

$1.3M

Revenue

39

Employees

1992

Founded

SWOT Analysis

Strengths

  • Committed strategic owner. Yuhan Corporation has put about KRW 60.5 bn into the company since 2015 and approved a further KRW 5.0 bn in July 2026 (Dailypharm).
  • Parent's financial capacity. Yuhan reported record FY2025 consolidated revenue of KRW 2,186.6 bn and operating income of KRW 104.4 bn (press, Feb 2026).
  • Existing CGMP-grade plant. The Osan plant was built for about KRW 3.8 bn and has run since March 2014, covering skin care and colour (Cosinkorea; Woori Investment & Securities).
  • Demonstrated ability to scale. Revenue rose from KRW 10.6 bn (FY2013) to KRW 109.3 bn (FY2019) with operating profits in FY2015–FY2019.
  • Restored audit credibility. FY2023 received an unqualified opinion after three disclaimers (Jangup Shinmun).
  • Clean post-rehabilitation slate. Rehabilitation concluded on 8 December 2023, with debt converted to equity under a court-approved plan (Jangup; Dailypharm).

Weaknesses

  • Collapsed revenue base. FY2025 revenue was KRW 1.9 bn, 98.3% below FY2019 (Dailypharm).
  • Losses larger than revenue. Q2 2026 operating loss of KRW 1.4 bn on KRW 0.4 bn of revenue.
  • Negative equity. -KRW 27.8 bn at end-Q1 2026, with liabilities of KRW 47.2 bn against assets of KRW 19.4 bn.
  • Six consecutive years of operating losses (FY2020–FY2025). Cumulative losses total about KRW 63.0 bn (14.7 + 15.0 + 9.6 + 7.0 + 5.9 + 5.8).
  • Governance legacy. Disclaimers on FY2020, H1 FY2021, FY2021, H1 FY2022 and FY2022 statements, plus a 2020 half-year review disclaimer (Chosun Biz; Edaily).
  • Thin disclosure. No public segment, geographic, R&D or cash-flow data since delisting, which makes the company hard for customers and lenders to underwrite.

Opportunities

  • Record K-beauty exports. US$11.4 bn in 2025 and +27% in H1 2026 (MFDS).
  • ODM sector growth. 81 tracked OEM/ODM firms grew revenue 11.8% and operating income 24.5% in FY2025 (Cosinkorea).
  • Indie brands outsourcing production. Smaller brands without plants are expanding abroad and outsourcing manufacturing (Economist Korea, Aug 2026).
  • Pharma-grade positioning. Safety-assessment regimes are tightening in the US and China, and Korea phases one in from 2028 (MFDS), which could reward pharmaceutical-standard QC.
  • Own-brand channel. Yucostory and "The Yu" (2026) add a direct-to-consumer revenue line with a KRW 1.0 bn brand budget (Dailypharm, Jul 2026).
  • Yuhan group synergies. Yuhan's household, health and pharmaceutical businesses could, in principle, become captive customers. No such contracts are disclosed.

Threats

  • Scale disadvantage. Cosmax (KRW 2,398.8 bn) and Kolmar Korea (KRW 2,722.4 bn) dominate, with margins of about 8–9%.
  • Funding dependence. Without continued Yuhan injections, negative equity and losses imply a going-concern risk (inference from end-Q1 2026 balance sheet).
  • Security-holder overhang. Sungwoo's KRW 10 bn BW plus warrants over 9.09 m shares; an attempted sale collapsed in April 2026 (Dailypharm).
  • RCPS redemption claims. The July 2026 RCPS can be redeemed from July 2028 at KRW 1,100 per share, creating a potential future cash claim.
  • Regulatory burden on customers. US importer-of-record changes could weigh on SME exporter clients (CNC News, 2026).
  • Parent strategy risk. Yuhan's capital allocation increasingly prioritises pharma R&D (for example the Lazertinib franchise), which could reduce tolerance for further cosmetics losses.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Aug–Sep 2025Rights issue of KRW 2.5 bn to Yuhan approved (second of 2025)Continued parent support
Sep 2025Dailypharm puts Yuhan's cumulative investment at about KRW 50.5 bnScale of sunk investment
Oct 2025KRW 5.0 bn rights issue to Yuhan (third of 2025; KRW 10.5 bn for the year)Liquidity runway
13 Oct 2025 (reported)Renamed Yuhan Cosmetics; new vision, values, co-CEOsStrategic reset; closer branding to Yuhan
Oct 2025Dailypharm puts cumulative Yuhan investment at about KRW 55.5 bn—
Q4 2025Yucostory established (100%, KRW 5 m)Entry into B2C
Jan–Feb 2026Industry reports record Korean cosmetics exports at a record US$11.4 bn for 2025Favourable market backdrop
Mar 2026"The Yu" vita-exosome products listed on Naver StoreFirst own brand since the Moonshot era
Mar 2026Press reports FY2025 revenue of about KRW 1.9 bn; cumulative FY2020–FY2024 operating losses about KRW 52.2 bnConfirms continued decline
Mar 2026Sungwoo Electronics decides to sell its Yuhan Cosmetics BW for KRW 15 bnSignals a possible change in a major security holder
Apr 2026Sungwoo BW sale cancelled after counterparty breachOverhang persists
Apr 2026Cosinkorea ODM survey: Yuhan Cosmetics revenue fell from KRW 4.0 bn to 1.9 bn (-53.2%) while the 81-firm ODM sector grew 11.8%Severe relative underperformance
Q1 2026 (filed)Revenue KRW 0.4 bn; operating loss KRW 0.9 bn; equity -KRW 27.8 bnComplete capital impairment
Q2 2026 (filed)Revenue KRW 0.4 bn; operating loss KRW 1.4 bnLosses widening quarter on quarter
Jun 2026Dailypharm reports large pharma companies entering K-beauty late (sector context)Relevant to Yuhan's strategic rationale
22 Jul 2026KRW 5.0 bn RCPS to Yuhan approved; proceeds for cell line, filling and testing equipment, new brandCapex restart
23 Jul 2026Dailypharm puts Yuhan's 11-year investment at about KRW 60 bn—
Oct 2026No further company-specific disclosures found as of 20 Oct 2026—
1 Apr 2024New management; "second founding day"Start of Yuhan-led era
Apr 2024FY2023 audit opinion unqualified, after three disclaimersRestores basic financial credibility
Jul 2024Sungwoo Electronics MOU and KRW 10 bn BWSecond strategic financier
8 Dec 2023Rehabilitation concludedCourt supervision ends
20 Oct 2023Delisted from KOSDAQLoss of public-market access

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment: Cosmetics manufacturing and sales revenue fell from KRW 7,500 Mn in FY2023 to KRW 1,900 Mn in FY2025.
COSON Co., Ltd. — Revenue by Segment
Series (KRW Mn)FY2023FY2024FY2025
Cosmetics manufacturing and sales revenue7,5004,0001,900
Cosmetics operating income-7,000-5,900-5,800

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Dailypharm, "11년새 600억 투자…유한, 화장품 자회사 재기 안간힘" (23 Jul 2026) (dailypharm.com)
  2. Dailypharm, "유한코스메틱 출범·자금 지원...유한, 화장품 회생 총력" (15 Oct 2025) (dailypharm.com)
  3. Dailypharm, "유한, 화장품 자회사 코스온 회생에 추가 자금 투입" (3 Sep 2025) (dailypharm.com)
  4. Dailypharm, "'투자 업체 회생'...유한, 휴대폰부품 기업과 손잡은 까닭" (19 Jul 2024) (dailypharm.com)
  5. Dailypharm, "유한, 5년전 인수 화장품업체 최대주주 상실한 사연" (20 Nov 2023) (m.dailypharm.com)
  6. Dailypharm, "타법인 최대주주 7건...유한양행의 정중동 M&A 행보" (7 Apr 2023) (dailypharm.com)
  7. Nate / press, "상폐 딛고 신사업…유한코스메틱, 자회사 설립·브랜드 론칭" (10 Mar 2026) (m.news.nate.com)
  8. Cosinkorea, ODM sector FY2025 results (Apr 2026) (cosinkorea.com)
  9. Cosinkorea, COSON liquidation trading (Oct 2023) (cosinkorea.com)
  10. Cosinkorea, 2017 OEM/ODM top-70 analysis (2018) (cosinkorea.mediaon.co.kr)
  11. Cosinkorea, Osan plant construction (cosinkorea.com)
  12. Hankyung, renaming to Yuhan Cosmetics (Oct 2025) (hankyung.com)
  13. Herald Economy, renaming to Yuhan Cosmetics (Oct 2025) (heraldk.com)
  14. Jangup Shinmun, COSON post-rehabilitation relaunch (Apr 2024) (jangup.com)
  15. Hitnews, Yuhan regains largest-shareholder position (Jan 2024) (hitnews.co.kr)
  16. Chosun Biz via Daum, "'GD쿠션'으로 대박났던 코스온, 상장폐지 수순" (Aug 2022) (v.daum.net)
  17. Chosun Biz via Daum, Hojeon Ltd decides not to acquire COSON (2021) (v.daum.net)
  18. Cosmorning, COSON injunction filing (Jan 2023) (cosmorning.com)
  19. Pharmnews, COSON delisting schedule (Dec 2022) (pharmnews.com)
  20. Edaily, injunction filing (edaily.co.kr)
  21. Edaily, objection and improvement period (edaily.co.kr)
  22. Edaily, improvement-plan review (edaily.co.kr)
  23. Edaily, listing-eligibility review cause (edaily.co.kr)
  24. Edaily, revenue passes KRW 100 bn (Mar 2018) (edaily.co.kr)
  25. Etoday, MINISO-driven growth (Mar 2018) (etoday.co.kr)
  26. Dealsite, KOSDAQ delisting decisions (Jan 2023) (dealsite.co.kr)
  27. Dealsite, delisting-risk companies (Apr 2023) (dealsite.co.kr)
  28. Dealsite, Audin Futures M&A termination (Mar 2020) (dealsite.co.kr)
  29. Dealsite, Lemonex MOU (dealsite.co.kr)
  30. Newstomato, FY2021 delisting-cause list (newstomato.com)
  31. Newstomato, Woori Investment & Securities report (Jun 2014) (newstomato.com)
  32. KIND, COSON Q1 FY2023 quarterly report (kind.krx.co.kr)
  33. Findata (DART), COSON Q1 FY2019 report (findata.co.kr)
  34. FnGuide, COSON company page (comp.fnguide.com)
  35. Mirae Asset weekly note on Yuhan's 2015 investment (securities.miraeasset.com)
  36. Cosmax press release, Cosmax–COSON MOU (Dec 2013) (cosmax.com)
  37. Cosmetics Business, Guangzhou Huanya JV (cosmeticsbusiness.com)
  38. Bizhankook, Moonshot launch (bizhankook.com)
  39. Refinery29, Moonshot and COSON (refinery29.com)
  40. Sports Kyunghyang, Moonshot at Lotte Duty Free (Jul 2015) (sports.khan.co.kr)
  41. New Daily, Moonshot re-launch and Sephora entry (Sep 2015) (newdaily.co.kr)
  42. Time Out Seoul, GD Cushion (timeout.com)
  43. Sidae, apM Group agreement (Jun 2016) (sidae.com)
  44. Sidae, Make Up in Seoul / Nelly Rodi (Apr 2015) (sidae.com)
  45. Cosmorning, FY2016 results of 107 cosmetics companies (cosmorning.com)
  46. Cosmorning, H1 2017 results of 46 cosmetics companies (cosmorning.com)
  47. Cosmorning, FY2017 results of 83 cosmetics companies (cosmorning.com)
  48. IRGO, COSON research report list (m.irgo.co.kr)
  49. Etnews, 2015 OEM/ODM year-end review (etnews.com)
  50. Newsprime, 3H FY2009 results (newsprime.co.kr)
  51. ETRI, DVR market trends (2009) (ettrends.etri.re.kr)
  52. Simply Wall St, A069110 (simplywall.st)
  53. Panjiva, Coson Co., Ltd. shipments (panjiva.com)
  54. EMIS, Coson Co., Ltd. profile (emis.cn)
  55. Incruit, COSON company info (jlab.incruit.com)
  56. Sidae, Cosmax FY2025 results (Feb 2026) (sidae.com)
  57. Herald Economy, Kolmar and Cosmax FY2025 results (Feb 2026) (heraldk.com)
  58. Economist Korea, ODM Q2 2026 results (Aug 2026) (economist.co.kr)
  59. Nate, Yuhan Corporation FY2025 results (Feb 2026) (m.news.nate.com)
  60. Newsseoul, MFDS 2025 cosmetics production and trade (newsseoul.co.kr)
  61. Newsis, 2025 cosmetics exports record (Jan 2026) (newsis.com)
  62. Cosmorning, MFDS 2025 export analysis (cosmorning.com)
  63. CNC News, H1 2026 cosmetics exports (cncnews.co.kr)
  64. CNC News, H1 2025 health-industry exports (cncnews.co.kr)
  65. Cosmorning, Intercos Korea Osan plant (cosmorning.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.